Baseline demographics of patients (FAS)
| Group A (n=96) | Group B (n=95) | Group C (n=50) | |
| Febuxostat dose increasing 10–40 mg | Febuxostat 40 mg+colchicine | Febuxostat 40 mg | |
| Age, mean (SD) | 47.4 (10.5) | 47.6 (11.1) | 46.4 (12.7) |
| Height, mean (SD), cm | 171.0 (5.7) | 170.8 (5.8) | 169.8 (6.9) |
| Weight, mean (SD), kg | 77.3 (12.4) | 76.5 (11.7) | 76.8 (16.4) |
| BMI, mean (SD), kg/m2 | 26.4 (3.6) | 26.2 (3.5) | 26.5 (5.1) |
| Systolic blood pressure, mean (SD), mm Hg | 132.6 (14.4) | 132.8 (16.3) | 132.6 (17.6) |
| Diastolic blood pressure, mean (SD), mm Hg | 84.5 (12.0) | 84.3 (11.9) | 82.6 (14.0) |
| Any history of ≥2 gout flares, n (%) | 74 (77.1) | 70 (73.7) | 38 (76.0) |
| Prior urate-lowering therapy, n (%) | 31 (32.3) | 31 (32.6) | 16 (32.0) |
| eGFR at entry, mean (SD), mL/min/1.73 m2 | 75.8 (16.2) | 76.6 (13.7) | 76.8 (17.5) |
| Serum urate at entry, mean (SD), mg/dL | 8.67 (1.38) | 8.51 (1.19) | 8.57 (1.17) |
| Serum creatinine at entry, mean (SD), mg/dL | 0.90 (0.16) | 0.88 (0.14) | 0.89 (0.15) |
| With any comorbidity, n (%) | 51 (53.1) | 47 (49.5) | 29 (58.0) |
BMI, body mass index; eGFR, estimated glomerular filtration rate; FAS, full analysis set.